ReviewOncology research2026
Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies.
Review in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Aurora A Kinase Enhance the CDK4/6 Inhibitor Sensitivity in HR+/HER2- Breast Cancer.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the primary cause of cancer-related mortality for women globally; therefore, further breakthroughs in treatment approaches are crucial. Palbociclib, ribociclib, and abemaciclib are among the Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive, Human Epidermal Growth factor receptor 2 (HR+/HER2-) breast cancer. These inhibitors work by preventing the action of CDK4/6, which are crucial in the regulation of the cell cycle. Leading cancer cells to cell cycle arrest and undergo apoptosis. When these inhibitors are used with endocrine medicines like letrozole and fulvestrant, clinical trials lead positive impact in progression-free survival and, in a few cases, complete survival. However, despite their effectiveness, resistance mechanisms are primary and current acquired problems, requiring combined approaches with additional targeted medicines and continuous investigation into innovative therapeutic plans. To maintain patient compliance and quality of life, common side effects such as tiredness, gastrointestinal problems, and neutropenia need to be effectively managed. There is hopefulness for wider oncological applications as next-generation CDK inhibitor development and adaptive clinical trials continue to test their potential beyond breast cancer. CDK4/6 inhibitors continue to be a key part of breast cancer treatment as cancer biology advances, marking a major advancement towards more potent and customized cancer medicines. This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2- breast cancer, highlighting their mechanisms, interaction with endocrine resistance, combination strategies, and emerging biomarkers guiding personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.